Yaoyanshe secures Series C+ & Series D, totaling RMB600m

Yaoyanshe, an innovative CRO platform, has raised more than 600 million yuan in consecutive rounds of Series C+ and Series D in the last eight months.
The Series D round was co-led by CGV Capital and Vision Capital, with participation from existing investors Matrix Partners China and Eastern Bell Venture Capital.

Yaoyanshe, an innovative CRO platform, has raised more than 600 million yuan in consecutive rounds of Series C+ and Series D in the last eight months.

The Series D round was co-led by CGV Capital and Vision Capital, with participation from existing investors Matrix Partners China and Eastern Bell Venture Capital.

The Series C+ round was co-led by Sequoia Capital China and Eastern Bell Venture Capital, with participation from existing investors Matrix Partners China, Vision Capital, Genesis Capital, among others.

Proceeds from this round of financing will continue to be used to strengthen the standardization and systematization of drug development and other infrastructure, promote clinical research technology platforms, and open and share them with the industry.

Founded in December 2015, Yaoyanshe is a developer of an online platform intended to integrate and share clinical research-based data. The company’s platform provides medical professionals with comprehensive pharmaceutical research data and offers patients the latest treatment options, enabling users to get access to extensive healthcare-related data easily.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/12/yaoyanshe-secures-series-c-series-d-totaling-rmb600m/.

Leave a Reply

Please Login to Comment